Search
Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalA full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. … Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may
Mixtures: CHAMPIX 0,5 MG 1 MG FILM KAPLI TABLET, 11 VE 14 ADET, CHAMPIX 0,5 MG 1 MG FILM KAPLI TABLET, 11 VE 14 ADETProducts: CHAMPIX 1 MG 56 FILM KAPLI TABLET, CHAMPIX 1.0 MG TABLETAS RECUBIERTASEmpagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigational[L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for … [A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).
Mixtures: GLYXAMBI® 10 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGProducts: JARDIANCE 10 MG, JARDIANCE 10 MG FILM KAPLI TABLET, 30 ADETTimolol
go.drugbank.com/drugs/DB00373ApprovedInvestigational[L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978. … [L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
Mixtures: AZARGA 10 MG/ML + 5 MG/ML, AZARGA 10 MG/ML+5 MG/ML STERİL SÜSPANSİYON GÖZ DAMLASI, 5 MLCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesNitisinone
go.drugbank.com/drugs/DB00348ApprovedNitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: NITISINONA 10 MG, NITISOR® 10 MG CAPSULASEthiodized oil
go.drugbank.com/drugs/DB00965ApprovedInvestigationalAnd although these esters are primarily as ethyl monoiodostearate and ethyl diiodostearate, the actual, specific structure is unknown. … Ethiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil.
Products: LİPİODUL ULTRA-FLUİD 480 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ, 10 ML, LİPİODUL ULTRA-FLUİD 480 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ , 5 MLRisankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigationalRisankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risan...
Products: Skyrizi 150 mg/ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 1 ADET, SKYRİZİ 150 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETSatralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalSatralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD. … This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single drug molecules to interact with multiple endogenous IL-6 receptors prior to elimination.
Products: ENSPRYNG 120 mg/1ml solution for injection in pre-filled syringe, ENSPRYNG 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETTocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L12789] It was later approved by Health Canada on 30 April 2010. … [A193281] Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersProducts: ACTEMRA 200 MG/10 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 1 ADET, ACTEMRA 200 MG/10 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 4 ADETLisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigational[A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine.
Products: VYVANSE CAPSULES 50 mg, Elvanse 50 mg HartkapselnFinasteride
go.drugbank.com/drugs/DB01216ApprovedInvestigationalIt works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. … Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone
Mixtures: Finasteride 0.1% / Minoxidil 5%, Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5%Categories: 5-alpha Reductase Inhibitors, Cytochrome P-450 Substrates